Fibrosis: Oncodesign and TiumBio sign collaboration agreement for R&D of drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates. This initial phase of the collaboration will be funded by TiumBio.
Specialized support and expert advice in the definition and design of preclinical studies for target validation, investigation of mechanisms of action, in vitro and in vivo pharmacodynamics and in vivo anti-inflammatory efficacy
Relevant analyses and readouts to assess the pharmacological activity of your products, covering:
clinical scoring analyses
assessment of effects at modulating of cytokine profile
effects on immune populations analyzed flow cytometry